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Abstract: Leptin, an adipose tissue hormone which regulates food intake, is also involved in the pathogenesis of arterial 
hypertension. Plasma leptin concentration is increased in obese individuals. Chronic leptin administration or transgenic 
overexpression increases blood pressure in experimental animals, and some studies indicate that plasma leptin is elevated 
in hypertensive subjects independently of body weight. Leptin has a dose- and time-dependent effect on urinary sodium 
excretion. High doses of leptin increase Na
+ excretion in the short run; partially by decreasing renal Na
+,K
+-ATPase 
(sodium pump) activity. This effect is mediated by phosphatidylinositol 3-kinase (PI3K) and is impaired in animals with 
dietary-induced obesity. In contrast to acute, chronic elevation of plasma leptin to the level observed in patients with the 
metabolic syndrome impairs renal Na
+ excretion, which is associated with the increase in renal Na
+,K
+-ATPase activity. 
This effect results from oxidative stress-induced deficiency of nitric oxide and/or transactivation of epidermal growth 
factor receptor and subsequent stimulation of extracellular signal-regulated kinases. Ameliorating “renal leptin resistance” 
or reducing leptin level and/or leptin signaling in states of chronic hyperleptinemia may be a novel strategy for the 
treatment of arterial hypertension associated with the metabolic syndrome. 
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LEPTIN AND ITS ROLE IN ARTERIAL 
HYPERTENSION 
  Overweight and obesity are the leading causes of arterial 
hypertension worldwide. It is estimated that in highly deve-
loped countries about 2/3 cases of essential hypertension can 
be attributed to excess body weight. Obesity becomes also an 
increasing contributor to hypertension in developing coun-
tries as well as in children and adolescents [1]. The patho-
genesis of obesity-associated hypertension is complex and 
incompletely understood, however, as in other forms of 
hypertension; abnormal renal sodium handling and disturbed 
regulation of the vascular tone play a predominant role [2]. 
Recent studies indicate that adipose tissue is not only a site 
of triglyceride storage but also an active endocrine organ 
which secretes multiple biologically active mediators called 
adipokines, such as leptin, adiponectin, resistin, visfatin, 
apelin, etc.; production of which is either up-regulated or 
downregulated in obese subjects [3]. At least some of these 
adipokines exert physiological effects on the cardiovascular 
system, and abnormalities of their production may contribute 
to the pathogenesis of obesity-associated complications. In 
this article I focus on the role of leptin – the first identified 
and the best characterized adipokine – in the regulation of 
renal Na
+ handling. I characterize physiological effects of 
leptin as well as its involvement in obesity-associated hyper-
tension. 
  Leptin was identified in 1994 by positional cloning of the 
ob gene responsible for the development of obesity in ob/ob 
mice [4]. It is produced by adipocytes in proportion to the  
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amount of adipose tissue and acts on hypothalamus to dec-
rease food intake and stimulate energy expenditure. Leptin 
binds to plasma membrane receptors existing in at least 6 
isoforms, Ob-Ra through Ob-Rf. The main or “long” iso-
form, Ob-Rb, contains the longest intracellular domain and, 
upon leptin binding, stimulates Janus kinases (JAK) which 
phosphorylate tyrosine residues of signal transducers and 
activators of transcription (STAT) proteins. Phosphorylated 
STAT proteins translocate to the nucleus and regulate trans-
cription of target genes. Short isoforms of the leptin receptor, 
Ob-Ra, Ob-Rc, Ob-Rd and Ob-Rf, have shorter intracellular 
domains and cannot activate JAK-STAT pathway but may 
perform signal transduction through other mechanisms such 
as phosphatidylinositol 3-kinase (PI3K), mitogen-activated 
protein kinases (MAPK), etc. Ob-Re is a soluble form of the 
leptin receptor which circulates in the blood and is a major 
leptin-binding protein. Apart from hypothalamus, leptin 
receptors are contained in many peripheral tissues including 
the cardiovascular system [5]. 
 Homozygous  ob/ob mice are extremely obese due to 
inherited lack of leptin. In contrast, animals with dietary-
induced obesity as well as most obese humans are charac-
terized by hyperleptinemia. Two other leptin-related animal 
models of obesity exist: db/db mice which lack Ob-Rb but 
have functional other receptor subtypes, and obese Zucker 
fa/fa rats bearing mutation within the extracellular domain of 
the leptin receptor which reduces the affinity for leptin of all 
receptor isoforms. Both these animal strains are severely 
obese, hyperleptinemic, leptin-resistant and insulin-resistant. 
  Several lines of evidence suggest the role of leptin in the 
pathogenesis of arterial hypertension: (1) chronic leptin 
administration [6] or transgenic overexpression [7] increases 
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increased in leptin-deficient ob/ob mice despite severe obe-
sity, and supplementation of leptin to these animals inc-
reases BP despite reducing body weight [8], (3) some studies 
indicate that plasma leptin concentration is higher in patients 
with arterial hypertension independently of body weight [9]. 
These data raise interest about possible effects of leptin in 
the cardiovascular system. 
ABNORMALITIES OF RENAL Na
+ HANDLING AND 
RENAL Na
+,K
+-ATPASE IN THE PATHOGENESIS OF 
ARTERIAL HYPERTENSION 
  Apart from vascular tone, renal sodium handling is the 
second major factor regulating blood pressure. Although 
determined by many factors including renal perfusion, 
glomerular filtration, etc., sodium excretion is regulated 
mainly at the level of renal tubules. More than 99% of fil-
tered Na
+ is normally reabsorbed throughout the nephron and 
thus even very small changes in the rate of reabsorption may 
cause marked alterations of Na
+ excretion leading ultimately 
to disturbances of Na
+ balance, extracellular fluid volume 
and blood pressure [10]. Sodium reabsorption is a two-step 
process: first Na
+ ions passively enter the tubular cells 
through transporters localized in the apical plasma mem-
brane and then are actively extruded from the cell to the 
peritubular space against the concentration gradient. 
Whereas passive transporters change along the nephron 
(sodium/proton exchanger, furosemide-sensitive sodium/-
potassium/chloride symporter, sodium/chloride symporter 
and epithelial sodium channel are predominant apical trans-
porters in the proximal convoluted tubule, medullary thick 
ascending limb, distal convoluted tubule and collecting duct, 
respectively), active step of Na
+ reabsorption is driven 
mainly by Na
+,K
+-ATPase in all nephron segments. Both 
steps of Na
+ transport are subjects to complex neurohor-
monal regulation. Indeed, most, if not all, hormones, media-
tors and neurotransmitters involved in the regulation of Na
+ 
balance affect apical passive transporters and/or basolateral 
Na
+,K
+-ATPase in specific nephron segments. Those factors 
which stimulate Na
+ transport (e.g. angiotensin II, catechola-
mines, mineralocorticoids, glucocorticoids) ultimately 
reduce sodium excretion and increase blood pressure, 
whereas other mediators such as dopamine, cardiac natriu-
retic peptides, nitric oxide, etc. have the opposite effect [11]. 
  Abnormalities of the regulation of Na
+ transport play a 
pivotal role in the pathogenesis of arterial hypertension. For 
example, Na
+,K
+-ATPase activity in the proximal tubule is 
higher in spontaneously hypertensive rat (SHR) than in 
normotensive Wistar-Kyoto rat even before the development 
of hypertension [12-14]. In addition, abundance of Na
+,K
+-
ATPase -subunit protein is greater in the proximal tubule of 
SHR [15]. Interestingly, in hypertensive rats a greater frac-
tion of total cellular Na
+,K
+-ATPase 1 subunit is contained 
in the basolateral membrane resulting in the enhancement of 
Na
+ transport [16]. In Dahl salt-sensitive rat, a glutamine for 
leucine substitution within the Na
+,K
+-ATPase  1 subunit 
gene is associated with enhanced Na
+ reabsorption [17-19]. 
In addition, inhibitory effect of dopamine on tubular sodium 
pump is impaired in both these rat models of genetic 
hypertension [20, 21]. Mutations within the gene encoding 
cytoskeletal protein adducin, which result in the enhanced 
Na
+ reabsorption, are observed in many hypertensive 
humans as well as in Milan hypertensive rat strain [22, 23]. 
These mutations increase the activity of Na
+,K
+-ATPase by 
impairing its endocytosis from the basolateral plasma mem-
brane to inactive intracellular pool [24, 25]. Several forms of 
monogenic hypertension in humans are also associated with 
the mutations of genes which encode sodium transporters or 
components of their regulatory pathways (e.g. gain-of-fun-
ction mutations of epithelial Na
+ channel in the Liddle synd-
rome or mutations of WNK kinases which increase the 
activity of thiazide-sensitive Na
+/Cl
- cotransporter in the 
Gordon’s syndrome). These data indicate that enhanced Na
+ 
reabsorption, in some cases induced by overactivation of 
sodium pump, plays a major role in the development of 
hypertension. 
  Abnormalities of sodium transport regulation have also 
been implicated in the pathogenesis of hypertension asso-
ciated with the metabolic syndrome. For example, the ability 
of dopamine to inhibit Na
+,K
+-ATPase-driven Na
+ reab-
sorption by tubular cells is impaired, whereas the stimulatory 
effect of angiotensin II is enhanced in obese insulin resistant 
Zucker  fa/fa rats [26, 27]. Strazzullo et al. [28] have 
demonstrated that Na
+ reabsorption in the proximal tubule is 
enhanced in men with abdominal obesity. It has also been 
shown that renal effect of atrial natriuretic peptide is 
impaired in obese subjects [29]. Taken together, these data 
indicate that abnormalities of renal Na
+ handling play an 
important role in the development of hypertension associated 
with the metabolic syndrome. 
ACUTE NATRIURETIC EFFECT OF LEPTIN 
  Many studies have demonstrated that although leptin 
stimulates sympathetic nervous system (SNS), it has no acute 
effect on blood pressure, which suggests that SNS activation 
is balanced by opposite depressor mechanisms. At least two 
such mechanisms have been described: stimulation of endo-
thelial nitric oxide production and natriuresis. Serradeil-Le 
Gal and coworkers [30] first identified specific leptin bin-
ding sites in the renal medulla and demonstrated significant 
increase in diuresis following intraperitoneal leptin injection 
in mice. Subsequently, several studies demonstrated that 
leptin administered intraperitoneally [31], intravenously [32, 
33], or locally into the renal artery [34] increased natriuresis 
without affecting renal blood flow, glomerular filtration rate 
and potassium excretion, suggesting that natriuretic effect of 
leptin results from inhibiting tubular Na
+ reabsorption. We 
have demonstrated that systemically [31, 35] or locally [36] 
administered leptin induces a time- and dose-dependent 
decrease in Na
+,K
+-ATPase activity in the renal medulla. 
Specific leptin binding sites were identified in the renal 
medulla, presumably in medullary collecting duct [37]. The 
effect of leptin on Na
+,K
+-ATPase is specific since leptin did 
not change the activity of ouabain-sensitive H
+,K
+-ATPase 
contained in the apical membranes and involved in K
+ 
reabsorption and urine acidification [35, 36]. 
  Since both natriuretic and Na
+,K
+-ATPase-inhibitory 
effects of leptin were too rapid to be accounted for by 
changes in gene expression – a target of classic JAK-STAT 
pathway triggered by the Ob-Rb – signaling mechanisms 
involved in these effects were further examined [36]. 
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cells, we first studied the role of NO-cGMP system, pre-
viously demonstrated to enhance natriuresis by inhibiting 
renal sodium pump [38-40]. However, leptin had no effect 
on urinary excretion of either NO metabolites or cGMP. In 
addition, inhibitors of NO synthase, soluble (NO-sensitive) 
guanylate cyclase and protein kinase G did not abolish 
natriuretic effect of leptin excluding the major role of NO-
cGMP pathway [36]. Moreover, leptin had no acute effect on 
plasma concentration of atrial natriuretic peptide (ANP) or 
urinary excretion of urodilatin (ANP-related peptide pro-
duced exclusively in the kidney), which stimulate membrane 
guanylate cyclase receptors [36]. Among other transduction 
pathways, inhibitors of protein kinases A or C as well as of 
cyclooxygenase or cytochrome P450-dependent arachidonate 
metabolism failed to abolish the effect of leptin. In contrast, 
two structurally unrelated inhibitors of phosphoinositide 3-
kinase, wortmannin or LY294002, prevented leptin-induced 
decrease in medullary Na
+,K
+-ATPase activity [36]. Sub-
sequently, we have demonstrated that wortmannin and LY2-
94002 abolish also the natriuretic effect of intravenously 
administered leptin [41]. Although protein kinase B/Akt is a 
common downstream kinase of PI3K, leptin had no effect on 
PKB/Akt phosphorylation in the renal medulla, and specific 
PKB/Akt inhibitor did not abolish natriuretic effect of leptin 
[41]. The precise mechanism through which PI3K mediates 
the effect of leptin is unclear. However, PI3K has been 
demonstrated to mediate dopamine-induced endocytosis of 
Na
+,K
+-ATPase in renal tubular cells [42]. PI3K binds to 
proline-rich motif of Na
+,K
+-ATPase  1-subunit and 
regulates its internalization. Although this effect requires 
enzymatic activity of PI3K, it is not dependent on PKB/Akt 
[43, 44]. 
  Physiological significance of acute natriuretic effect of 
leptin is incompletely understood, especially because this 
effect is exerted at hormone concentrations markedly exce-
eding the physiological range. However, Villarreal et al. [45] 
have demonstrated that blockade of endogenous leptin by a 
specific antibody reduced natriuresis induced in the rat by 
mild volume expansion. In addition, leptin expression in 
adipose tissue increases in response to high-salt diet [46]. 
These data suggest that renal effect of leptin may be relevant 
for maintaining Na
+ balance, especially after ingesting a 
high-salt meal. 
RESISTANCE TO ACUTE NATRIURETIC EFFECT 
OF LEPTIN 
  In contrast to leptin-deficient ob/ob mice, plasma leptin 
concentration is significantly elevated in animals with die-
tary-induced obesity as well as in obese humans reflecting 
the state of hypothalamic leptin resistance. Correia et al. [47] 
proposed that obesity is accompanied by selective leptin 
resistance, i.e. impairment of appetite-suppressing effect and 
preserved sympathoexcitatory activity. This might lead, due 
to hyperleptinemia, to overactivation of the SNS and BP 
elevation. This concept has been confirmed by the experi-
ments performed in agouti obese mice. In these animals, 
agouti protein – an endogenous melanocortin receptor anta-
gonist normally expressed only in the skin - is ectopically 
expressed and blocks the anorectic effect of leptin-melan-
ocortin pathway mediated by hypothalamic melanocortin 
receptors. Consequently, agouti mice are obese, hype-
rinsulinemic and leptin-resistant. In these animals either 
peripherally [47] or intracerebroventricularly [48] admini-
stered leptin exerts less marked effects on food intake and 
body weight but stimulates renal sympathetic nervous 
activity similarly as in lean wild-type controls. Selective 
leptin resistance was also observed in mice made obese by 
high-fat diet [49]. In addition, in the latter study chronic 
leptin administration increased BP to the similar extent in 
lean and obese groups, suggesting that renal sympathetic 
nervous activity is crucial for BP elevation and that acute 
hypertensive effect of leptin is not affected by leptin 
resistance.
 
  Although initial studies suggested that resistance of 
hypothalamic centers to anorectic effect of circulating leptin 
is mainly associated with impaired hormone transport across 
the blood - brain barrier, later studies demonstrated that 
leptin resistance is also observed following central admini-
stration of this hormone due to receptor or postreceptor 
signaling defects. These data, together with increasing 
number of peripheral effects of leptin being described, led us 
to ask if natriuretic effect of leptin is preserved or impaired 
in obesity. To address this issue, we tested the effect of leptin 
in rats made obese by feeding highly palatable diet for 4 
weeks [31]. This model of obesity is characterized by 
moderate increase in body weight and plasma leptin 
concentration but plasma glucose, lipid profile, insulin 
concentration and basal blood pressure are still normal. 
Thus, this model represents early uncomplicated phase of 
obesity and the results are not confounded by abnormalities 
of carbohydrate and lipid metabolism, insulin resistance, etc. 
We observed that the effects of intraperitoneally admini-
stered leptin on natriuresis and renal medullary Na
+,K
+-
ATPase were impaired in obese animals. Thus, leptin resis-
tance is not confined to the CNS but involves also some 
peripheral actions of this hormone [31].
 
  The mechanism of leptin resistance at the renal level is 
not clear at present. Prolonged hyperleptinemia associated 
with obesity may result in the downregulation of leptin 
receptors or postreceptor signaling mechanisms. For exa-
mple, reduced number of leptin receptors was observed in 
the kidney of obese rats [50] and dogs [51]. Resistance to 
natriuretic effect of leptin was also observed in spontan-
eously hypertensive rats, and renal denervation restored 
sensitivity to leptin in these animals [52], suggesting that 
increased renal sympathetic activity counteracts natriuretic 
effect of leptin. Among postreceptor signaling pathways, two 
mechanisms attracted special attention as potential 
contributors to leptin resistance: suppressor of cytokine 
signaling-3 (SOCS-3), and protein tyrosine phosphatase-1B 
(PTP-1B) [5].
  SOCS-3 is induced upon activation of the 
leptin receptor and inhibits leptin signaling by binding to the 
receptor itself as well as to the key downstream kinase, 
JAK2. SOCS-3 is overexpressed in the hypothalamus in 
various models of leptin resistance such as dietary-induced 
obesity. PTP-1B dephosphorylates proteins phosphorylated 
after activation of the leptin receptor such as JAK2 and 
STAT-3. However, role of SOCS-3 or PTP-1B in resistance 
to peripheral effects of leptin remains unclear. 
  Recently, we examined if prolonged hyperleptinemia 
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absence of obesity. Preliminary results suggest that chronic 
(7-day) administration of exogenous leptin impairs acute 
increase in natriuresis and decrease in renal medullary 
Na
+,K
+-ATPase activity after subsequent bolus intravenous 
leptin administration. In addition, pretreatment with 1-
adrenergic antagonist, prazosin, or NADPH oxidase inhibitor 
and antioxidant, apocynin, failed to improve these effects, 
suggesting that neither oxidative stress nor sympathetic 
nervous system are involved in renal leptin resistance in this 
model (Betowski  et al. manuscript submitted for public-
cation). In addition, because rats chronically pretreated with 
leptin have normal or even improved insulin sensitivity, 
these data suggest that hyperinsulinemia and insulin 
resistance are not necessary to induce renal leptin resistance 
in obese animals. This conclusion is in contrast to that 
obtained by studying the mechanism of resistance to 
natriuretic effect of dopamine, which is mediated by both 
hyperinsulinemia and oxidative stress [53, 54]. 
ANTINATRIURETIC EFFECT OF CHRONIC 
HYPERLEPTINEMIA 
  Although resistance to natriuretic effect of leptin may 
contribute to the development of hypertension due to unop-
posed stimulation of the SNS, the effect of chronically 
elevated leptin on renal function seems more important if 
pathogenesis of hypertension associated with the metabolic 
syndrome is considered. Early studies have demonstrated 
that chronic central or peripheral leptin infusion had no 
effect on sodium excretion despite elevating blood pressure 
[6, 55]. These data indicate that leptin impairs pressure-nat-
riuresis relationship - an abnormality common for many 
types of hypertension.  
  We examined the effect of leptin administered for 7 days 
at a dose of 0.5 mg/kg/day (plasma leptin concentration 
about four times higher than normally) on renal Na
+ handling 
in the rat. We found that leptin treatment reduced both 
absolute and fractional Na
+ excretion, which was accom-
panied by the increase in renal cortical and, especially, 
medullary Na
+,K
+-ATPase activity [56, 57]. Further studies 
have demonstrated that this antinatriuretic effect of leptin is 
mediated by reactive oxygen species (ROS)-dependent 
scavenging of intrarenally produced NO. This conclusion is 
supported by the following observations: (1) leptin increased 
markers of intrarenal oxidative stress and nitrotyrosine (the 
product of protein nitration by peroxynitrite, which 
originates in the reaction between NO and superoxide) con-
centration, (2) leptin reduced renal NO and its second 
messenger, cGMP, levels (3) antinatriuretic effect of leptin 
was abolished by apocynin (NADPH oxidase inhibitor) and 
tempol (scavenger of superoxide anion radical) [58, 59]. 
Previously, we [38] and others [60] have demonstrated that 
NO produced locally within the kidney exerts a tonic inhi-
bitory effect on tubular Na
+ transport and Na
+,K
+-ATPase, 
and that this effect of NO is limited by superoxide anion 
radical (O2
-•) continuously produced by NADPH oxidase – a 
multimeric enzyme which is a predominant source of ROS in 
the cardiovascular system and the kidney [61, 62]. In 
addition,  -adrenergic receptor antagonist, prazosion, nor-
malized Na
+,K
+-ATPase activity in the renal cortex of leptin-
treated rats, indicating that leptin may stimulate sodium 
pump in part by activating SNS. 
ROLE OF ERKs IN ANTINATRIURETIC EFFECT OF 
LEPTIN 
  `To get more insight into the mechanism through which 
leptin stimulates renal Na
+,K
+-ATPase, we examined the 
effect of leptin infused locally into the renal artery [63]. As 
mentioned previously [36], short-term (30 min) hormone 
infusion resulted in the decrease in sodium pump activity 
specifically in the renal medulla. However, when leptin infu-
sion was prolonged to 3 hours, Na
+,K
+-ATPase activity 
increased in both renal cortex and medulla, indicating that 
the effect of leptin is time-dependent. Both inhibitory and 
stimulatory effects of leptin were abolished by JAK 
inhibitor, AG490. However, only inhibitory effect was abo-
lished by PI3K inhibitors. Unexpectedly, although NADPH 
oxidase inhibitor, apocynin, abolished the stimulatory effect 
of leptin, superoxide scavengers, tempol, or superoxide dis-
mutase, augmented it. These results suggest that ROS other 
than superoxide are involved in Na
+,K
+-ATPase stimulation. 
Because both tempol and SOD convert superoxide to hyd-
rogen peroxide (H2O2), we hypothesized that H2O2 might be 
involved. Indeed, leptin increased urinary H2O2 excretion, 
and its stimulatory effect on Na
+,K
+-ATPase was abolished 
by catalase and mimicked by H2O2 [63]. Furthermore, we 
demonstrated that the effect of either leptin or H2O2 was 
abolished by extracellular signal-regulated kinase (ERK) 
inhibitors, PD98059 or U0126, but not by p38 MAPK 
inhibitor, SB203580. Taken together, these results suggest 
that the stimulatory effect of locally infused leptin on renal 
sodium pump is mediated by H2O2-dependent activation of 
ERK rather than by O2
-•-induced scavenging of NO [63]. 
TIME-DEPENDENCY OF THE MECHANISM 
THROUGH WHICH LEPTIN STIMULATES RENAL 
Na
+,K
+-ATPASE - ROLE OF ANTIOXIDANT 
ENZYMES 
  To resolve why O2
-•-NO mechanism predominates after 
7-day systemic leptin administration [57] and H2O2-ERK 
dependent one after local 3-hour hormone infusion [63], we 
examined the effect of locally infused leptin in control 
animals as well as in rats made hyperleptinemic by preceding 
7-day systemic leptin treatment [64]. Using combined 
biochemical and pharmacological approaches, we demon-
strated that leptin infused locally to the renal artery stimu-
lated cortical and medullary Na
+,K
+-ATPase through the 
H2O2-ERK dependent mechanism in normal rats but through 
the O2
-•-NO mechanism in previously hyperleptinemic rats, 
which suggests that the mechanism of antinatriuretic effect 
of leptin changes time-dependently when hormone is admini-
stered for prolonged time period. Indeed, in the recent study 
[65] we found that if leptin was administered systemically, 
H2O2-ERK mechanism predominates after 4 days, and O2
-•-
NO mechanism after 8 days of hormone administration. The 
effect of leptin was abolished by NADPH oxidase inhibitor 
at both time points, however, tempol was effective only if 
leptin was administered for 8 days but further aggravated its 
effect after 4 days. In contrast, ERK inhibitor, PD98059, 
reduced Na
+,K
+-ATPase activity and normalized blood 
pressure in rats receiving leptin for 4 days but not for 8 days 
These data suggest that leptin induces NADPH oxidase-
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vation of ERK and O2
-•-induced NO deficiency predominate 
after 4 and 8 days of leptin administration, respectively.  
  Because NADPH oxidase generates only superoxide 
which is further converted to H2O2 by superoxide dismutase 
(SOD), we looked at the activities of antioxidant enzymes in 
the kidney of leptin-treated rats. We found that SOD activity 
was reduced whereas glutathione peroxidase (GPx) activity 
was increased in the kidney of rats treated with leptin for 8 
days but these activities were unchanged in animals recei-
ving leptin for 4 days. This suggests that relative contri-
bution of H2O2-ERK vs. O2
-•-NO mechanisms is determined 
by antioxidant enzyme activities. In animals receiving leptin 
for 4 days, SOD and GPx activities are unchanged which 
probably makes H2O2 (more stable than superoxide) the 
predominant ROS. In contrast, reduced SOD and increased 
GPx activity after 8 days of leptin administration favors 
formation of O2
-• instead of H2O2 (which is formed by SOD 
and decomposed by GPx) [65]. Changes of SOD and GPx 
expression/activities may be a compensatory mechanism 
aimed to limit oxidative injury since H2O2 is more damaging 
than superoxide. Indeed, markers of lipid peroxidation in 
renal tissue were lower in the 8-day than in the 4-day leptin-
treated group [65]. 
  Glutathione (GSH) is a major intracellular antioxidant 
and ROS sensor. Indeed, the ratio between reduced (GSH) 
and oxidized (GSSG) glutathione determines oxidation state 
of protein sulfhydryl groups involved in redox signaling. 
Therefore, in subsequent studies we asked if glutathione 
redox status is affected by leptin treatment and how does it 
contribute to alterations of antioxidant enzymes. In a very 
recent study [66] we have demonstrated that GSH/GSSG 
ratio markedly decreases in the kidney of rats receiving 
leptin for 4 days, whereas in those receiving hormone for 8 
days it is partially restored. This restoration is associated 
with the up-regulation of a rate-limiting enzyme in GSH 
synthesis, -glutamylcysteine synthetase (-GCS). Moreover, 
if GSH synthesis is suppressed by -GCS inhibitor, 
buthionine sulfoximine, leptin-induced changes of SOD and 
GPx are accelerated, i.e. occur already after 4 days of 
hormone administration, which is accompanied by the shift 
from H2O2-ERK to O2
-•-NO dependent mechanism of leptin-
induced antinatriuresis and Na
+,K
+-ATPase stimulation. In 
contrast, if GSH precursor, N-acetylcysteine, is administered 
together with leptin, it partially corrects fall in GSH/GSSG 
ratio and prevents changes in SOD and GPx even at the 8
th 
day of leptin treatment. Consequently, H2O2-ERK dependent 
mechanism still operates in the 8-day leptin group [66]. 
Taken together, these results indicate that changes in GSH 
redox status determine decrease in SOD and increase in GPx 
activities after leptin treatment, which has profound 
consequences for the mechanism through which leptin 
reduces natriuresis and elevates blood pressure (Fig. (1)). 
EFFECT OF GRADUAL INCREASE IN PLASMA 
LEPTIN CONCENTRATION 
  In all studies mentioned above leptin was administered at 
a constant dose of 0.5 mg/kg/day. Because in patients with 
the metabolic syndrome plasma leptin increases progress-
sively other the long period of time, gradually increasing 
leptin dosage seems to be a more physiologically relevant 
approach. We demonstrated that if leptin is administered at 
progressively increasing doses, SOD and GPx activities are 
unchanged even after 12 days of hormone administration. 
Although renal Na
+,K
+-ATPase activity and blood pressure 
are elevated to the similar extent as in rats receiving leptin at 
a constant dose, H2O2-ERK mechanism still operates after 12 
days of leptin treatment at progressively increasing doses. It 
is likely that if leptin dose is progressively increased, the 
cells can better handle the oxidative stress, e.g. by nonen-
zymatic antioxidants, and compensatory changes of SOD 
and GPx do not occur [66].  
  These considerations are potentially important from 
therapeutic point of view. Although oxidative stress is 
clearly involved in the pathogenesis of cardiovascular 
diseases, the clinical outcome in trials with antioxidants was 
generally disappointing [67]. One of the reasons may be that 
some antioxidants such as tempol scavenge only some spe-
cific ROS and may even generate the others. It seems that 
more selective antioxidant therapy, targeting specific ROS 
and signaling pathways triggered by them, may be a more 
appropriate therapeutic approach than nonspecific anti-
oxidants such as ascorbate or vitamin E examined in 
previous trials. 
ROLE OF EPIDERMAL GROWTH FACTOR 
RECEPTOR (EGFR) IN RENAL EFFECT OF LEPTIN 
  Many mechanisms of H2O2-induced activation of ERKs 
have been described in the literature, and ERKs have been 
implicated in the pathogenesis of various forms of 
experimental hypertension. To unravel the mechanism 
through which leptin activates ERKs in the kidney, we 
focused on epidermal growth factor receptor (EGFR). EGFR 
is a member of membrane-bound receptor tyrosine kinase 
family which is abundantly expressed in the vascular wall 
and renal tubular cells. Upon ligand binding, EGFR 
undergoes autophosphorylation at several tyrosine residues 
within its intracellular domain and triggers various signaling 
pathways including ERK. Stimulation of EGFR results in the 
recruitment of adaptor proteins Grb2 and Sos, which interact 
with and activate membrane-bound Ras protein. Activated 
Ras stimulates phosphorylation cascade including protein 
kinases Raf, MEK and ERK1/2 [68]. Several lines of 
evidence suggest the role of EGFR in arterial hypertension. 
First, apart from its cognate ligand, EGFR may be activated 
by many mediators involved in the regulation of vascular 
tone and renal Na
+ transport such as angiotensin II, 
endothelin-1 and norepinephrine; the phenomenon referred 
to as transactivation. Second, increased expression and/or 
activity of EGFR were reported in various experimental 
models of hypertension, and EGFR inhibitors reduce blood 
pressure in some of these models [69]. Finally, leptin has 
been demonstrated to transactivate EGFR in several cancer 
cell lines as well as in vascular smooth muscle cells [70]. 
  We have demonstrated that the effect of leptin on renal 
ERK and Na
+,K
+-ATPase is abolished by EGFR inhibitors, 
AG1478 or PD158780, and is mimicked by EGF [71]. There 
are two major mechanisms of EGFR transactivation: (1) 
stimulation of metalloproteases which generate peptide 
EGFR ligands from their membrane-bound precursors, and 
(2) activation by reactive oxygen species of non-receptor 36    Current Cardiology Reviews, 2010, Vol. 6, No. 1  Jerzy Betowski 
tyrosine kinase Src, which phosphorylates intracellular 
domain of EGFR. Therefore, we further studied which of 
these mechanisms is triggered by leptin. We found that leptin 
stimulates EGFR phosphorylation at Tyr
845 (the principal Src 
phosphorylation site) and, to a lesser extent, at Tyr
1068 (one 
of autophosphorylation sites) [72]. In addition, the effects of 
leptin on EGFR phosphorylation, ERK phosphorylation and 
renal Na
+,K
+-ATPase were abolished by specific Src 
inhibitor, PP2, as well as by H2O2 scavenger, catalase, but 
not by metalloprotease inhibitor, GM6001. Both leptin and 
H2O2 increased Src phosphorylation at Tyr
418 (a marker of 
Src activity). Taken together, these results indicate that 
leptin-induced activation of EGFR is mediated by ROS 
(presumably H2O2), and Src kinase [71, 72]. 
  Finally, we asked if inhibitors of EGFR-ERK pathway 
can normalize renal Na
+,K
+-ATPase activity, natriuresis and 
blood pressure in rats receiving leptin. For this purpose, 
leptin was administered at progressively increasing doses for 
10 days and blood pressure and renal Na
+,K
+-ATPase were 
measured. We found that apocynin, PP2 or AG1478 reduced 
blood pressure, increased Na
+ excretion and decreased renal 
Na
+,K
+-ATPase activity in leptin-treated animals. In con-
trast, GM6001 did not attenuate leptin-induced increase in 
EGFR phosphorylation nor did it modulate the effect of 
leptin on renal sodium pump or sodium handling. These data 
indicate that inhibiting Src-EGFR pathway may be a pote-
ntial therapeutic strategy for arterial hypertension associated 
with hyperleptinemic states such as metabolic syndrome or 
type 2 diabetes. 
RENAL RESISTANCE TO NATRIURETIC PEPTIDES 
IN CHRONIC HYPERLEPTINEMIA 
  Apart from NO, atrial natriuretic peptide (ANP) and a 
related intrarenally produced peptide, urodilatin, inhibit Na
+ 
reabsorption through the cGMP-PKG dependent mechanism 
[73]. Interestingly, in our model of chronic hyperleptinemia 
plasma ANP and urinary urodilatin concentrations were 
increased [56, 57]. Reduced natriuresis and renal cGMP 
generation despite increased ANP suggest that the kidneys 
become resistant to natriuretic peptides following leptin 
treatment. Indeed, increase in cGMP and Na
+ excretion in 
response to exogenous ANP was less marked in hyper-
leptinemic than in control rats [74]. This effect was corrected 
by inhibitor of cGMP-specific phosphodiesterase (PDE5), 
zaprinast, suggesting that enhanced cGMP degradation by 
PDE5 is responsible for this phenomenon. In addition, 
resistance to ANP and its correction by zaprinast were 
observed in rats made obese by high-calorie diet thus 
indicating that hyperleptinemia could contribute to renal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The mechanism of leptin-induced stimulation of renal Na
+,K
+-ATPase and BP elevation in rats receiving a constant dose of leptin 
for 4 or 8 days. Leptin stimulates superoxide (O2
-•) production by NADPH oxidase. In the 4-day group, O2
-• is rapidly converted by 
superoxide dismutase (SOD) to hydrogen peroxide (H2O2), which stimulates extracellular signal-regulated kinases (ERK). ERK activate 
renal Na
+,K
+-ATPase leading to the increase in Na
+ reabsorption and BP elevation. Simultaneously, H2O2 and/or H2O2-induced oxidative 
stress reduces the ratio between reduced glutathione (GSH) and glutathione disulfide (GSSG). Reduced GSH/GSSG ratio induces decrease in 
SOD and increase in GPx activity. Consequently, in the 8-day group H2O2 is efficiently metabolized while O2
-• becomes a predominant ROS 
formed. Superoxide reacts with nitric oxide (NO) to form peroxynitrite (ONOO
-). Because NO inhibits renal Na
+,K
+-ATPase, its deficiency 
results in Na
+,K
+-ATPase stimulation and BP elevation. Role in the Pathogenesis of Arterial Hypertension  Current Cardiology Reviews, 2010, Vol. 6, No. 1    37 
unresponsiveness to natriuretic peptides observed in obese 
subjects [74]. Although increased PDE5-dependent cGMP 
degradation is a common mechanism of renal unres-
ponsiveness to ANP in various disease states, the mechanism 
through which leptin enhances PDE5 is unclear. Inter-
estingly, natriuretic effect of synthetic NO donor was intact 
in either leptin-treated or obese rats, indicating that various 
intracellular pools of cGMP mediate the effects of ANP and 
NO on renal Na
+ transport. 
LEPTIN AND THE REGULATION OF RENAL 
OUABAIN-RESISTANT NA
+-ATPASE IN PHYSIO-
LOGICAL AND PATHOLOGICAL CONDITIONS 
  Apart from Na
+,K
+-ATPase, renal tubules contain the 
second sodium pump, ouabain-resistant Na
+-ATPase. Unlike 
Na
+,K
+-ATPase, Na
+-ATPase transports sodium but not 
potassium, in not inhibited by Na
+,K
+-ATPase inhibitor, 
ouabain, but is sensitive to loop diuretics such as furosemide, 
and is expressed only in the proximal tubule but not in other 
nephron segments [75]. Although this enzyme transport only 
10-15% of sodium reabsorbed in the proximal tubule, 
changes in its activity may cause marked alterations of nat-
riuresis. The mechanisms regulating Na
+-ATPase are poorly 
characterized; however, its activity is affected by many 
mediators controlling Na
+ balance such as angiotensin II, 
nitric oxide and natriuretic peptides [75]. 
  We have demonstrated that acutely administered leptin 
does not change renal Na
+-ATPase activity suggesting that 
this pump is not involved in acute natriuretic effect of leptin 
[76]. In contrast, Na
+-ATPase activity was increased in the 
renal cortex of rats treated with leptin for 7 days [76]. Using 
pharmacological inhibitors of various signaling pathways, 
we have demonstrated that, similarly to Na
+,K
+-ATPase, 
Na
+-ATPase stimulation in hyperleptinemic rats results from 
O2
-  -dependent NO deficiency. However, in contrast to 
Na
+,K
+-ATPase which is inhibited by NO in the cGMP-PKG 
dependent manner, Na
+-ATPase is inhibited by NO-cGMP 
pathway through the PKG-independent mechanism. Rather, 
cGMP stimulates phosphodiesterase 2 which degrades 
cAMP and removes its tonic stimulatory effect on ouabain-
resistant Na
+ pump [77]. Leptin stimulates ROS formation 
leading to NO degradation, and thus downregulates this inhi-
bitory mechanism. Consequently, the stimulatory effect of 
cAMP on ouabain-resistant Na
+-ATPase is enhanced (Fig. 
(2)). 
CLINICAL AND THERAPEUTIC IMPLICATIONS 
  Although the relationship between high serum leptin and 
hypertension has been reported in many human studies [78, 
79], it is unknown if chronic hyperleptinemia affects renal 
function in humans. In one study [80], plasma leptin was 
inversely correlated with lithium clearance, which suggests 
that high leptin was associated with increased Na
+ 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Effect of chronic hyperleptinemia on renal tubular Na
+-transporting pumps. Leptin stimulates NADPH oxidase (NOX) which 
generates superoxide anion radical (O2
-). Superoxide reacts with nitric oxide (NO) to form peroxynitrite (ONOO
-) and thus curtails the 
inhibitory effect of NO on active sodium reabsorption. NO stimulates soluble guanylyl cyclase (sGC) to generate cGMP, and cGMP inhibits 
both Na
+,K
+-ATPase and ouabain-resistant Na
+-ATPase. However, Na
+,K
+-ATPase is inhibited in protein kinase G (PKG)-dependent 
manner whereas Na
+-ATPase is inhibited because cGMP stimulates (in PKG-independent manner) phosphodiesterase 2 (PDE2) and 
decreases cAMP concentration. Apart from NO, cGMP synthesis is stimulated by atrial natriuretic peptide (ANP) binding to membrane 
receptors (particulate guanylyl cyclase, pGC). Hyperleptinemia induces resistance to ANP by stimulating degradation of cGMP by 
phosphodiesterase 5 (PDE5). The scheme presents mechanisms operating in different nephron segments; Na
+,K
+-ATPase is inhibited by 
ANP in the medullary collecting duct whereas Na
+-ATPase is expressed only in the proximal tubule. Localization of ANP and leptin 
receptors demonstrated above does not necessarily reproduce their real localization in polarized tubular cells but was chosen arbitrarily for 
better clarity. 38    Current Cardiology Reviews, 2010, Vol. 6, No. 1  Jerzy Betowski 
reabsorption in the proximal tubule. These findings suggest 
that chronically elevated leptin has antinatriuretic effect in 
humans. 
  Given all data presented above, it could be suggested that 
two therapeutic strategies may be proposed to target leptin 
signaling in hypertension: (1) improving beneficial 
natriuretic effect of this hormone, i.e. reducing renal leptin 
resistance, (2) reducing chronically elevated leptin in 
patients with the metabolic syndrome or interrupting leptin 
signaling involved in the enhancement of Na
+ reabsorption 
to reduce detrimental effect of chronic hyperleptinemia. 
Until now, only weight loss seems to fulfill both these 
criteria. Currently it is unclear how we could improve 
natriuretic effect of leptin. Possibly, targeting intracellular 
pathways involved in leptin resistance such as SOCS-3 or 
PTP1B may be a useful strategy in the future. More 
promising seems to be inhibiting signaling pathways 
triggered by chronic hyperleptinemia which drive enhanced 
Na
+ reabsorption, e.g. by EGFR, ERK or Src inhibitors, as 
well as by antioxidants. 
  However, leptin signaling may also be affected by less 
specific therapies. The effect of many currently used 
antihypertensive drugs on plasma leptin has been examined. 
However, interpretation of results is not easy since decrease 
in plasma leptin can result from various mechanisms such as: 
(1) direct inhibition of leptin production by adipose tissue, 
(2) compensatory response of adipose tissue to improved 
leptin signaling in the hypothalamus, (3) an indirect effect of 
the drug resulting for example from changes in adiposity, 
insulin sensitivity, etc. Until now, it has been demonstrated 
that at least some angiotensin-converting enzyme inhibitors, 
angiotensin AT1 receptor antagonists, calcium antagonists 
and -adrenergic receptor antagonists decrease plasma leptin 
level [81]. The effect of -adrenergic receptor antagonists is 
controversial since both increase and decrease in leptin have 
been reported, whereas thiazide diuretics have no effect. It is 
possible that modulation of leptin signaling contributes to 
beneficial effect of some of these therapies on the 
cardiovascular system. 
REFERENCES 
[1]  Genovesi S, Pieruzzi F.  Obesity-associated hypertension in 
childhood: A new epidemic problem. Curr Hypertens Rev 2006; 2: 
199-206. 
[2]  Seki G, Yamada H, Li Y, Horita S, Suzuki M, Toshiro F. The roles 
of abnormal renal sodium handling in hypertension associated with 
metabolic syndrome. Curr Hypertens Rev 2008; 4: 197-202. 
[3]  Wilson AM, Ryan MC. The role of adipokines in hypertension and 
cardiovascular disease. Curr Hypertens Rev 2007; 3: 208-15. 
[4]  Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman 
JM. Positional cloning of the mouse obese gene and its human 
homologue. Nature 1994; 372: 425-32. 
[5]  Myers MG, Cowley MA, Münzberg H. Mechanisms of leptin action 
and leptin resistance. Annu Rev Physiol 2008; 70: 537-56. 
[6]  Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases 
arterial pressure. Hypertension 1998; 31: 409-14. 
[7]  Aizawa-Abe M, Ogawa Y, Masuzaki H, et al. Pathophysiological 
role of leptin in obesity-related hypertension. J Clin Invest 2000; 
105: 1243-52. 
[8]  Mark AL, Shaffer RA, Correia ML, Morgan DA, Sigmund CD, 
Haynes WG. Contrasting blood pressure effects of obesity in leptin-
deficient ob/ob mice and agouti yellow obese mice. J Hypertens 
1999; 17: 1949-53. 
[9]  Agata J, Masuda A, Takada M, et al. High plasma immunoreactive 
leptin level in essential hypertension. Am J Hypertens 1997; 10: 
1171-74. 
[10]  Meneton P, Jeunemaitre X, de Wardener HE, MacGregor GA. 
Links between dietary salt intake, renal salt handling, blood 
pressure, and cardiovascular diseases. Physiol Rev 2005; 85: 679-
715. 
[11]  Féraille E, Doucet A. Sodium-potassium-adenosinetriphosphatase-
dependent sodium transport in the kidney: hormonal control. 
Physiol Rev 2001; 81: 345-418. 
[12]  Garg LC, Narang N, McArdle S. Na-K-ATPase in nephron 
segments of rats developing spontaneous hypertension. Am J 
Physiol 1985; 249: F863–F869. 
[13]  Beach RE, DuBose TJ. Adrenergic regulation of Na
+,K
+-ATPase 
activity in proximal tubules of spontaneously hypertensive rats. 
Kidney Int 1990; 38: 402–8. 
[14]  Magyar CE, Zhang Y, Holstein-Rathlou NH, McDonough AA. 
Proximal tubule Na transporter responses are the same during acute 
and chronic hypertension. Am J Physiol Renal Physiol 2000; 279: 
F358–F369.  
[15]  Hayward AL, Hinojos CA, Nurowska B, et al. Altered sodium 
pump alpha and gamma subunit gene expression in nephron 
segments from hypertensive rats. J Hypertens 1999; 17: 1081–7. 
[16]  Hinojos CA, Doris PA. Altered subcellular distribution of Na
+,K
+-
ATPase in proximal tubules in young spontaneously hypertensive 
rats. Hypertension 2004; 44: 95-100. 
[17]  Ruiz-Opazo N, Barany F, Hirayama K, Herrera VL. Confirmation 
of mutant alpha 1 Na,K-ATPase gene and transcript in Dahl salt-
sensitive/JR rats. Hypertension 1994; 24: 260-70. 
[18]  Orosz DE, Hopfer U. Pathophysiological consequences of changes 
in the coupling ratio of Na,K-ATPase for renal sodium reabsorption 
and its implications for hypertension. Hypertension 1996; 27: 219-
27. 
[19]  Kaneko Y, Cloix JF, Herrera VL, Ruiz-Opazo N. Corroboration of 
Dahl S Q276L alpha1Na,K-ATPase protein sequence: impact on 
affinities for ligands and on E1 conformation. J Hypertens 2005; 
23: 745-52.  
[20]  Nishi A, Eklöf AC, Bertorello AM, Aperia A. Dopamine regulation 
of renal Na
+,K
+-ATPase activity is lacking in Dahl salt-sensitive 
rats. Hypertension 1993; 21: 767-71. 
[21]  Hussain T, Kansra V, Lokhandwala MF. Renal dopamine receptor 
signaling mechanisms in spontaneously hypertensive and Fischer 
344 old rats. Clin Exp Hypertens 1999; 21: 25-36. 
[22]  Manunta P, Citterio L, Lanzani C, Ferrandi M. Adducin polymor-
phisms and the treatment of hypertension. Pharmacogenomics 
2007; 8: 465-72. 
[23]  Ferrandi M, Salardi S, Tripodi G, et al. Evidence for an interaction 
between adducin and Na
+-K
+-ATPase: relation to genetic 
hypertension. Am J Physiol 1999; 277: H1338-49.  
[24]  Efendiev R, Krmar RT, Ogimoto G, et al. Hypertension-linked 
mutation in the adducin alpha-subunit leads to higher AP2-mu2 
phosphorylation and impaired Na
+,K
+-ATPase trafficking in 
response to GPCR signals and intracellular sodium. Circ Res 2004; 
95: 1100-8. 
[25]  Torielli L, Tivodar S, Montella RC, et al. alpha-Adducin mutations 
increase Na/K pump activity in renal cells by affecting constitutive 
endocytosis: implications for tubular Na reabsorption. Am J Physiol 
Renal Physiol 2008; 295: F478-87. 
[26]  Marwaha A, Lokhandwala MF. Diminished natriuretic response to 
dopamine D1 receptor agonist, SKF-38393 in obese Zucker rats. 
Clin Exp Hypertens 2003; 25: 509-15. 
[27]  Shah S, Hussain T. Enhanced angiotensin II-induced activation of 
Na
+,K
+-ATPase in the proximal tubules of obese Zucker rats. Clin 
Exp Hypertens 2006; 28: 29-40. 
[28]  Strazzullo P, Barba G, Cappuccio FP, et al. Altered renal sodium 
handling in men with abdominal adiposity: a link to hypertension. J 
Hypertens 2001; 19: 2157-64. 
[29]  Dessì-Fulgheri P, Sarzani R, Serenelli M, et al. Low calorie diet 
enhances renal, hemodynamic, and humoral effects of exogenous 
atrial natriuretic peptide in obese hypertensives. Hypertension 1999; 
33: 658-62. 
[30]  Serradeil-Le Gal C, Raufaste D, Brossard G, et al. Characterization 
and localization of leptin receptors in the rat kidney. FEBS Lett 
1997; 404: 185-91. 
[31]  Betowski J, Wójcicka G, Górny D, Marciniak A. Human leptin 
administered intraperitoneally stimulates natriuresis and decreases Role in the Pathogenesis of Arterial Hypertension  Current Cardiology Reviews, 2010, Vol. 6, No. 1    39 
renal medullary Na
+, K
+-ATPase activity in the rat -- impaired 
effect in dietary-induced obesity. Med Sci Monit 2002; 8: BR221-
BR229. 
[32]  Villarreal D, Reams G, Freeman RH, Taraben A. Renal effects of 
leptin in normotensive, hypertensive, and obese rats. Am J Physiol 
1998; 275: R2056-R2060. 
[33]  Be	towski J, Jochem J, Wójcicka G, wirska-Korczala K. Influence 
of intravenously administered leptin on nitric oxide production, 
renal hemodynamics and renal function in the rat. Regul Pept 2004; 
120: 59-67. 
[34]  Jackson EK, Li P. Human leptin has natriuretic activity in the rat. 
Am J Physiol 1997; 272: F333-F338. 
[35]  Be	towski J, Wójcicka G. Spectrophotometric method for the 
determination of renal ouabain-sensitive H
+,K
+-ATPase activity. 
Acta Biochim Pol 2002; 49: 515-527. 
[36]  Be	towski J, Marciniak A, Wójcicka G. Leptin decreases renal 
medullary Na
+, K
+-ATPase activity through phosphatidylinositol 3-
kinase dependent mechanism. J Physiol Pharmacol 2004; 55: 391-
407. 
[37]  Martinez-Anso E, Lostao MP, Martinez JA. Immunohistochemical 
localization of leptin in rat kidney. Kidney Int 1999; 55: 1129-30. 
[38]  Be	towski J, Marciniak A, Wójcicka G, Górny D. Nitric oxide 
decreases renal medullary Na
+,K
+-ATPase activity through cyclic 
GMP-protein kinase G dependent mechanism. J Physiol Pharmacol 
2003; 54: 191-210. 
[39]  Varela M, Herrera M, Garvin JL. Inhibition of Na-K-ATPase in 
thick ascending limbs by NO depends on O2- and is diminished by 
a high-salt diet. Am J Physiol Renal Physiol. 2004; 287: F224-30. 
[40]  Hakam AC, Hussain T. Angiotensin II AT2 receptors inhibit 
proximal tubular Na
+-K
+-ATPase activity via a NO/cGMP-
dependent pathway. Am J Physiol Renal Physiol 2006; 290: F1430-
6. 
[41]  Be	towski J, Wójcicka G, Jamroz-Winiewska A, Borkowska E. 
Role of PI3K and PKB/Akt in acute natriuretic and NO-mimetic 
effects of leptin. Regul Pept 2007; 140: 168-77. 
[42]  Chibalin AV, Zierath JR, Katz AI, Berggren PO, Bertorello AM. 
Phosphatidylinositol 3-kinase-mediated endocytosis of renal 
Na
+,K
+-ATPase alpha subunit in response to dopamine. Mol Biol 
Cell 1998; 9: 1209-20. 
[43]  Yudowski GA, Efendiev R, Pedemonte CH, Katz AI, Berggren PO, 
Bertorello AM. Phosphoinositide-3 kinase binds to a proline-rich 
motif in the Na
+,K
+-ATPase alpha subunit and regulates its 
trafficking. Proc Natl Acad Sci USA 2000; 97: 6556-61. 
[44]  Efendiev R, Chen Z, Krmar RT, et al. The 14-3-3 protein translates 
the Na
+,K
+-ATPase 1-subunit phosphorylation signal into binding 
and activation of phosphoinositide 3-kinase during endocytosis. J 
Biol Chem 2005; 280: 16272-7. 
[45]  Villarreal D, Reams G, Freeman R, et al. Leptin blockade 
attenuates sodium excretion in saline-loaded normotensive rats. Mol 
Cell Biochem 2006; 283:153-7. 
[46]  Dobrian AD, Schriver SD, Lynch T, Prewitt RL. Effect of salt on 
hypertension and oxidative stress in a rat model of diet-induced 
obesity. Am J Physiol Renal Physiol 2003; 285:F619-28. 
[47]  Correia ML, Haynes WG, Rahmouni K, Morgan DA, Sivitz WI, 
Mark AL. The concept of selective leptin resistance: evidence from 
agouti yellow obese mice. Diabetes 2002; 51:439-42. 
[48]  Rahmouni K, Haynes WG, Morgan DA, Mark AL. Selective 
resistance to central neural administration of leptin in agouti obese 
mice. Hypertension 2002; 39: 486-90. 
[49]  Rahmouni K, Morgan DA, Morgan GM, Mark AL, Haynes WG. 
Role of selective leptin resistance in diet-induced obesity 
hypertension. Diabetes 2005; 54: 2012-18. 
[50]  Coatmellec-Taglioni G, Dausse JP, Giudicelli Y, Ribiere C. Sexual 
dimorphism in cafeteria diet-induced hypertension is associated 
with gender-related difference in renal leptin receptor down-
regulation. J Pharmacol Exp Ther 2003; 305:362-7. 
[51]  Gu JW, Wang J, Stockton A, Lokitz B, Henegar L, Hall JE. 
Cytokine gene expression profiles in kidney medulla and cortex of 
obese hypertensive dogs. Kidney Int 2004; 66: 713-21. 
[52]  Villarreal D, Reams G, Freeman RH. Effects of renal denervation 
on the sodium excretory actions of leptin in hypertensive rats. 
Kidney Int 2000; 58: 989-94. 
[53]  Banday AA, Marwaha A, Tallam LS, Lokhandwala MF. Tempol 
reduces oxidative stress, improves insulin sensitivity, decreases 
renal dopamine D1 receptor hyperphosphorylation, and restores D1 
receptor-G-protein coupling and function in obese Zucker rats. 
Diabetes 2005; 54: 2219-26. 
[54]  Umrani DN, Banday AA, Hussain T, Lokhandwala MF. 
Rosiglitazone treatment restores renal dopamine receptor function 
in obese Zucker rats. Hypertension 2002; 40: 880-5. 
[55]  Kuo JJ, Jones OB, Hall JE. Inhibition of NO synthesis enhances 
chronic cardiovascular and renal actions of leptin. Hypertension 
2001; 37: 670-6. 
[56]  Be	towski J, Jamroz-Winiewska A, Borkowska E, Wójcicka G. 
Up-regulation of renal Na
+,K
+-ATPase: the possible novel 
mechanism of leptin-induced hypertension. Pol J Pharmacol 2004; 
56: 213-22. 
[57]  Beltowski J, Wójcicka G, Marciniak A, Jamroz A. Oxidative stress, 
nitric oxide production, and renal sodium handling in leptin-
induced hypertension. Life Sci 2004; 74: 2987-3000. 
[58]  Be	towski J, Jamroz-Winiewska A, Borkowska E, Nazar J, 
Marciniak A. Antioxidant treatment normalizes renal Na
+,K
+-
ATPase activity in leptin-treated rats. Pharmacol Rep 2005; 57: 
219-28. 
[59]  Beltowski J, Wójcicka G, Jamroz-Winiewska A, Borkowska E, 
Marciniak A. Antioxidant treatment normalizes nitric oxide 
production, renal sodium handling and blood pressure in 
experimental hyperleptinemia. Life Sci 2005; 77: 1855-68. 
[60]  Herrera M, Ortiz PA, Garvin JL. Regulation of thick ascending 
limb transport: role of nitric oxide. Am J Physiol Renal Physiol 
2006; 290: F1279-84. 
[61]  Garvin JL, Ortiz PA. The role of reactive oxygen species in the 
regulation of tubular function. Acta Physiol Scand 2003; 179: 225-
32. 
[62]  Be	towski J, Marciniak A, Jamroz-Winiewska A, Borkowska E. 
Nitric oxide -- superoxide cooperation in the regulation of renal 
Na
+,K
+-ATPase. Acta Biochim Pol 2004; 51: 933-42. 
[63]  Marciniak A, Jamroz-Winiewska A, Borkowska E, Be	towski J. 
Time-dependent effect of leptin on renal Na
+,K
+-ATPase activity. 
Acta Biochim Pol 2005; 52: 803-9. 
[64]  Marciniak A, Borkowska E, Kedra A, Rychlik M, Beltowski J. 
Time-dependent transition from H2O2-extracellular signal-regulated 
kinase- to O-nitric oxide-dependent mechanisms in the stimulatory 
effect of leptin on renal Na
+K
+-ATPase in the rat. Clin Exp 
Pharmacol Physiol 2006; 33: 1216-24. 
[65]  Wójcicka G, Jamroz-Winiewska A, Widomska S, Ksiazek M, 
Be	towski J. Role of extracellular signal-regulated kinases (ERK) in 
leptin-induced hypertension. Life Sci 2008; 82: 402-12. 
[66]  Be	towski J, Jamroz-Winiewska A, Wójcicka G, Lowicka E, 
Wojtak A. Renal antioxidant enzymes and glutathione redox status 
in leptin-induced hypertension. Mol Cell Biochem 2008; 319: 163-
74. 
[67]  Meydani M. Vitamin E modulation of cardiovascular disease. Ann 
N Y Acad Sci 2004; 1031:271-9. 
[68]  Fernandez-Patron C. Therapeutic potential of the epidermal growth 
factor receptor transactivation in hypertension: a convergent 
signaling pathway of vascular tone, oxidative stress, and 
hypertrophic growth downstream of vasoactive G-protein-coupled 
receptors? Can J Physiol Pharmacol 2007; 85: 97-104. 
[69]  Kim J, Lee CK, Park HJ, et al. Epidermal growth factor induces 
vasoconstriction through the phosphatidylinositol 3-kinase-
mediated mitogen-activated protein kinase pathway in hypertensive 
rats. J Pharmacol Sci 2006; 101: 135-43. 
[70]  Chao HH, Hong HJ, Liu JC, et al. Leptin stimulates endothelin-1 
expression  via extracellular signal-regulated kinase by epidermal 
growth factor receptor transactivation in rat aortic smooth muscle 
cells. Eur J Pharmacol 2007; 573: 49-54. 
[71]  Be	towski J, Wójcicka G, Trzeciak J, Marciniak A. H2O2 and Src-
dependent transactivation of the EGF receptor mediates the 
stimulatory effect of leptin on renal ERK and Na
+,K
+-ATPase. 
Peptides 2006; 27: 3234-44. 
[72]  Jamroz-Winiewska A, Wójcicka G, owicka E, Ksi

ek M, 
Be	towski J. Transactivation of epidermal growth factor receptor in 
vascular and renal systems in rats with experimental 
hyperleptinemia: role in leptin-induced hypertension. Biochem 
Pharmacol 2008; 75: 1623-38. 
[73]  Be	towski J, Wójcicka G. Regulation of renal tubular sodium 
transport by cardiac natriuretic peptides: two decades of research. 
Med Sci Monit 2002; 8: RA39-52. 
[74]  Be	towski J, Jamroz-Wisniewska A, Borkowska E, Marciniak A. 
Phosphodiesterase 5 inhibitor ameliorates renal resistance to atrial 40    Current Cardiology Reviews, 2010, Vol. 6, No. 1  Jerzy Betowski 
natriuretic peptide associated with obesity and hyperleptinemia. 
Arch Med Res 2006; 37:307-15. 
[75]  De Souza AM, Carvalho TL, Sabino PM, et al. Characterization 
and partial isolation of ouabain-insensitive Na
+-ATPase in MDCK I 
cells. Biochimie 2007; 89: 1425-32. 
[76]  Betowski J, Jamroz-Winiewska A, Nazar J, Wójcicka G. 
Spectrophotometric assay of renal ouabain-resistant Na
+-ATPase 
and its regulation by leptin and dietary-induced obesity. Acta 
Biochim Pol 2004; 51: 1003-14. 
[77]  Betowski J, Borkowska E, Wójcicka G, Marciniak A. Regulation 
of renal ouabain-resistant Na
+-ATPase by leptin, nitric oxide, 
reactive oxygen species, and cyclic nucleotides: implications for 
obesity-associated hypertension. Clin Exp Hypertens 2007; 29: 189-
207. 
[78]  Patel SB, Reams GP, Spear RM, Freeman RH, Villarreal D. Leptin: 
linking obesity, the metabolic syndrome, and cardiovascular 
disease. Curr Hypertens Rep 2008; 10: 131-7. 
[79]  Betowski J. Role of leptin in blood pressure regulation and arterial 
hypertension. J Hypertens 2006; 24: 789-801. 
[80]  El-Gharbawy AH, Kotchen JM, Grim CE, et al. Gender-specific 
correlates of leptin with hypertension-related phenotypes in African 
Americans. Am J Hypertens 2002; 15: 989-93. 
[81]  Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease: 
response to therapeutic interventions. Circulation 2008; 117: 3238-
49. 
 
 
Received: April 7, 2009  Revised: August 3, 2009          Accepted: August 3, 2009 
 
 
 